• 1
    Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 125132.
  • 2
    Whitehead WE, Holtkotter B, Enck P et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990; 98: 118792.
  • 3
    Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 4052.
  • 4
    Bradette M, Paré P, Douville P, Morin A. Visceral perception in health and functional dyspepsia. Crossover study of gastric distension in functional dyspepsia. Gastroenterology 2002; 121: 52635.
  • 5
    Mearin F, Cucala M, Azpiroz F, Malagelada JR. The origin of symptoms on the brain-gut axis in functional dyspepsia. Gastroenterology 1991; 101: 9991006.
  • 6
    Lemann M, Dederding JP, Flourie B, Franchisseur C, Rambaud JC, Jian R. Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. The irritable stomach syndrome. Dig Dis Sci 1991; 36: 124954.
  • 7
    Bouin M, Plourde V, Boivin M et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 17717.
  • 8
    Bouin M, Lupien F, Riberdy-Poitras M, Poitras P. Tolerance to gastric distension in patients with functional dyspepsia: modulation by a cholinergic and nitrergic method. Eur J Gastroenterol Hepatol 2006; 18: 638.
  • 9
    Gwee KA, Leong YL, Graham C et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 4006.
  • 10
    Mearin F, Perez-Oliveras M, Perello A et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129: 98104.
  • 11
    Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 80411.
  • 12
    Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693702.
  • 13
    Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 177883.
  • 14
    Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 19729.
  • 15
    Accarino AM, Azpiroz F, Malagelada JR. Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. Gastroenterology 1995; 108: 63643.
  • 16
    Cook IJ, Van Eeden A, Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology 1987; 93: 72733.
  • 17
    Bouin M, Delvaux M, Blanc C et al. Intrarectal injection of glycerol induces hypersensitivity to rectal distension in healthy subjects without modifying rectal compliance. Eur J Gastroenterol Hepatol 2001; 13: 57380.
  • 18
    Verne GN, Robinson ME, Vase L, Price DD. Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients. Pain 2003; 105: 22330.
  • 19
    Fukudo S, Kanazawa M, Kano M et al. Exaggerated motility of the descending colon with repetitive distention of the sigmoid colon in patients with irritable bowel syndrome. J Gastroenterol 2002; 37 (Suppl. 14): 14550.
  • 20
    Poitras P, Riberdy Poitras M, Plourde V, Boivin M, Verrier P. Evolution of visceral sensitivity in patients with irritable bowel syndrome. Dig Dis Sci 2002; 47: 91420.
  • 21
    Poitras MR, Verrier P, So C, Paquet S, Bouin M, Poitras P. Group counseling psychotherapy for patients with functional gastrointestinal disorders: development of new measures for symptom severity and quality of life. Dig Dis Sci 2002; 47: 1297307.
  • 22
    Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 21928.
  • 23
    Creed F, Fernandes L, Guthrie E et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124: 30317.
  • 24
    Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers A, Janssens J. A controlled cross-over study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55: 1095103.
  • 25
    Wieckowska A, Faure C. Study of visceral sensitivity in pediatric patients. Gastroenterology 2005; 128 (Suppl. 2): A110 (abstract).
  • 26
    Moriarty KJ, Dawson AM. Functional abdominal pain: further evidence that whole gut is affected. Br Med J (Clin Res Ed) 1982; 284: 16702.
  • 27
    Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995; 40: 160713.
  • 28
    Holtmann G, Goebell H, Talley NJ. Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis? Am J Gastroenterol 1997; 92: 9549.
  • 29
    Bouin M, Lupien F, Riberdy M, Boivin M, Plourde V, Poitras P. Intolerance to visceral distension in functional dyspepsia or irritable bowel syndrome: an organ specific defect or a pan intestinal dysregulation? Neurogastroenterol Motil 2004; 16: 3114.
  • 30
    Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 6716.
  • 31
    Fried M, Beglinger C, Bobalj NG et al. Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome. Eur J Gastroenterol Hepatol 2005; 17: 4217.
  • 32
    Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004; (1): CD003960.
  • 33
    Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 103540.
  • 34
    Lembo T, Wright RA, Bagby B et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 266270.
    Direct Link:
  • 35
    Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005; 100: 11523.
    Direct Link:
  • 36
    Bouin M, Meunier P, Riberdy-Poitras M, Poitras P. Pain hypersensitivity in patients with functional gastrointestinal disorders: a gastrointestinal-specific defect or a general systemic condition? Dig Dis Sci 2001; 46: 25428.
  • 37
    Verne GN, Robinson ME, Price DD. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 2001; 93: 714.
  • 38
    Chang L, Mayer EA, Johnson T, FitzGerald LZ, Naliboff B. Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. Pain 2000; 84: 297307.
  • 39
    Camilleri M, Atanasova E, Carlson PJ et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123: 42532.
  • 40
    Holtmann G, Siffert W, Haag S et al. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004; 126: 9719.
  • 41
    Kellow JE, Eckersley CM, Jones MP. Enhanced perception of physiological intestinal motility in the irritable bowel syndrome. Gastroenterology 1991; 101: 16217.
  • 42
    Naliboff BD, Munakata J, Fullerton S et al. Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut 1997; 41: 50512.
  • 43
    Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998; 115: 126371.
  • 44
    Derbyshire SW. A systematic review of neuroimaging data during visceral stimulation. Am J Gastroenterol 2003; 98: 1220.
    Direct Link:
  • 45
    Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 2005; 9: 46384.
  • 46
    Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science 2000; 288: 176972.
  • 47
    Verne GN, Himes NC, Robinson ME et al. Central representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome. Pain 2003; 103: 99110.
  • 48
    Naliboff BD, Derbyshire SWG, Munakata J et al. Cerebral activation in irritable bowel syndrome patients and control subjects during rectosigmoid stimulation. Psychosom Med 2001; 63: 36575.
  • 49
    Mayer EA, Berman S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD, Chang L. Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005; 115: 398409.
  • 50
    Mertz H, Morgan V, Tanner G et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distension. Gastroenterology 2000; 118: 8428.
  • 51
    Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 271293.
  • 52
    Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 2004; 25: 6137.
  • 53
    Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci 2002; 25: 31925.
  • 54
    Tracey I. Nociceptive processing in the human brain. Curr Opin Neurobiol 2005; 15, 47887.
  • 55
    Verne GN, Robinson ME, Price DD. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 2001; 93: 714.
  • 56
    Munakata J, Naliboff B, Harraf F et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997; 112: 5563.
  • 57
    Zubieta JK, Smith YR, Bueller JA et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 2001; 293: 3115.
  • 58
    Tracey I, Dunckley P. Importance of anti- and pro-nociceptive mechanisms in human disease. Gut 2004; 53: 15535.
  • 59
    Phillips ML, Gregory LJ, Cullen S et al. The effect of negative emotional context on neural and behavioural responses to oesophageal stimulation. Brain 2003; 126, 66984.
  • 60
    Derbyshire SW. A systematic review of neuroimaging data during visceral stimulation. Am J Gastroenterol 2003; 98: 1220.
    Direct Link:
  • 61
    Gregory LJ, Yaguez L, Williams SC et al. Cognitive modulation of the cerebral processing of human oesophageal sensation using functional magnetic resonance imaging. Gut 2003; 52, 16717.
  • 62
    Naliboff BD, Chang L, Munakata J, Mayer EA. Towards an integrative model of irritable bowel syndrome. In: MayerEA, SaperCB, eds. The Biological Basis for Mind Body Interactions. Amsterdam: Elsevier Science, 2000: 41323.
  • 63
    Ploghaus A, Becerra L, Borras C, Borsook D. Neural circuitry underlying pain modulation: expectation, hypnosis, placebo. Trends Cogn Sci 2003; 7: 197200.
  • 64
    Sawamoto N, Honda M, Okada T et al. Expectation of pain enhances responses to nonpainful somatosensory stimulation in the anterior cingulate cortex and parietal operculum/posterior insula: an event-related functional magnetic resonance imaging study. J Neurosci 2000; 20: 743845.
  • 65
    Wilder-Smith CH, Schindler D, Lovblad K, Redmond SM, Nirkko A. Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 2004; 53: 1595601.
  • 66
    Naliboff BD, Berman S, Chang L et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003; 124: 173847.
  • 67
    Mayer EA, Berman S, Chang L, Naliboff BD. Sex-based differences in gastrointestinal pain. Eur J Pain 2004; 8: 45163.
  • 68
    Naliboff BD, Berman S, Derbyshire SWG et al. Longitudinal changes in perceptual and brain responses to visceral stimulation in irritable bowel syndrome patients. Gastroenterology 2006; 131: 35265.
  • 69
    Newton M, Kamm MA, Soediono PO, Milner P, Burnham WR, Burnstock G. Oesophageal epithelial innervation in health and reflux esophagitis. Gut 1999; 44: 31722.
  • 70
    Fass R, Naliboff B, Higa L et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998; 115: 136373.
  • 71
    Drewes AM, Reddy H, Pedersen J, Funch-Jensen P, Gregersen H, Arendt-Nielsen L. Multimodal pain stimulations in patients with grade B esophagitis. Gut 2006; 55: 92633.
  • 72
    Sarkar S, Hobson AR, Furlong PL, Woolf CJ, Thompson DG, Aziz Q. Central neural mechanisms mediating human visceral hypersensitivity. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1196202.
  • 73
    Matthews PJ, Aziz Q, Facer P, Davis JB, Thompson DG, Anand P. Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human esophagus. Eur J Gastroenterol Hepatol 2004; 16: 897902.
  • 74
    Bercik P, De Giorgio R, Blennerhassett P, Verdu EF, Barbara G, Collins SM. Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection. Gastroenterology 2002; 123: 120515.
  • 75
    Rhee PL, Kim YH, Son HJ et al. Lack of association of Helicobacter pylori infection with gastric hypersensitivity or delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 1999; 94: 31659.
    Direct Link:
  • 76
    Mearin F, De Ribot X, Balboa A et al. Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia? Gut 1995; 37: 4751.
  • 77
    De Giorgio R, Barbara G, Blennerhassett P et al. Intestinal inflammation and activation of sensory nerve pathways: a functional and morphological study in the nematode infected rat. Gut 2001; 49: 8227.
  • 78
    Miampamba M, Sharkey KA. Distribution of calcitonin gene-related peptide, somatostatin, substance P and vasoactive intestinal polypeptide in experimental colitis in rats. Neurogastroenterol Motil 1998; 10: 31529.
  • 79
    Rao SS, Read NW, Davison PA, Bannister JJ, Holdsworth CD. Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis. Gastroenterology 1987; 93: 12705.
  • 80
    Bernstein CN, Robert ME, Eysselein VE. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 1993; 88: 90813.
  • 81
    Watanabe T, Kubota Y, Muto T. Substance P containing nerve fibers in rectal mucosa of ulcerative colitis. Dis Colon Rectum 1997; 40: 71825.
  • 82
    Kimura M, Masuda T, Hiwatashi N, Toyota T, Nagura H. Changes in neuropeptide-containing nerves in human colonic mucosa with inflammatory bowel disease. Pathol Int 1994; 44: 62434.
  • 83
    Mantyh CR, Vigna SR, Maggio JE, Mantyh PW, Bollinger RR, Pappas TN. Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors. Neurosci Lett 1994; 178: 2559.
  • 84
    Chang L, Munakata J, Mayer EA et al. Perceptual responses in patients with inflammatory and functional bowel disease. Gut 2000; 47: 497505.
  • 85
    Coffin B, Bouhassira D, Sabate JM, Barbe L, Jian R. Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome. Gut 2004; 53: 146570.
  • 86
    Bernstein CN, Niazi N, Robert M et al. Rectal afferent function in patients with inflammatory and functional intestinal disorders. Pain 1996; 66: 15161.
  • 87
    Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 16519.
  • 88
    Wheatcroft J, Wakelin D, Smith A, Mahoney CR, Mawe G, Spiller R. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 2005; 17: 86370.
  • 89
    Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096101.
  • 90
    Park JH, Poong-Lyul R, Jun HL, Jae JK, Seung WP, Jong CR. Enterochromaffin cell counts correlate with visceral hypersensitivity in patients with diarrhoea predominant irritable bowel syndrome (D-IBS). 20th International Symposium on Neurogastroenterology & Motility, 50. 2005.
  • 91
    Keating C, Foley S, Rieff-Marginiec A et al. Time dependent changes in jejunal afferent mechanosensitivity in mice infected with the nematode Trichinella spiralis. Gastroenterology 2005; 125 (Suppl. 2): A101.
  • 92
    Simpson J, Neal KR, Scholefield JH, Spiller RC. Patterns of pain in diverticular disease and the influence of acute diverticulitis. Eur J Gastroenterol Hepatol 2003; 15: 100510.
  • 93
    Simpson J, Sundler F, Jenkins D, Scholefield JH, Spiller RC. Increased expression of substance P, neuropeptide K and galanin in mucosal nerves in patients with painful diverticular disease. Gastroenterology 2004; 126: A218.
  • 94
    Clemens CH, Samsom M, Roelofs J, Berge Henegouwen GP, Smout AJ. Colorectal visceral perception in diverticular disease. Gut 2004; 53: 71722.
  • 95
    Kellow JE, Delvaux M, Azpiroz F, Camilleri M, Thompson DG, Quigley EM. Principles of applied neurogastroenterology: physiology/motility-sensation. In: DrossmanDA, CorazziariE, TalleyNJ, ThompsonWG, WhiteheadWE, eds. The Functional Gastrointestinal Disorders. Mc Lean, VA: Degnon Associates, 2000: 91156.
  • 96
    Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ III. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101: 92734.
  • 97
    Lembo T, Naliboff B, Munakata J et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999; 94: 13206.
    Direct Link:
  • 98
    Suarez F, Levitt MD. Intestinal gas. In: FeldmanM, FriedmanLS, SleisengerMH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management, 7th edn. Philadelphia, PA: W.B. Saunders Co., 2002: 15563.
  • 99
    Azpiroz F, Malagelada JR. Abdominal bloating. Gastroenterology 2005; 129: 106078.
  • 100
    Levitt MD. Volume and composition of human intestinal gas determined by means of an intestinal washout technic. N Engl J Med 1971; 284: 13948.
  • 101
    Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48: 149.
  • 102
    Suarez FL, Springfield J, Levitt MD. Identification of gases responsible for the odour of human flatus and evaluation of a device purported to reduce this odour. Gut 1998; 43: 1004.
  • 103
    Kirk E. The quantity and composition of human colonic flatus. Gastroenterology 1949; 12: 78294.
  • 104
    Steggerda FR. Gastrointestinal gas following food consumption. Ann NY Acad Sci 1968; 150: 5766.
  • 105
    Levitt MD. Follow-up of a flatulent patient. Dig Dis Sci 1979; 24: 6524.
  • 106
    Pouderoux P, Ergun GA, Shezhang L, Kahrilas PJ. Esophageal bolus transit imaged by ultrafast computerized tomography. Gastroenterology 1996; 110: 14228.
  • 107
    Fordtran JS, Morawski SG, Ana CAS, Rector FC. Gas-production after reaction of sodium-bicarbonate and hydrochloric-acid. Gastroenterology 1984; 87: 101421.
  • 108
    Foster RE. Physiological basis of gas exchange in the gut. Ann NY Acad Sci 1968; 150: 412.
  • 109
    Pogrund RS, Steggerda FR. Influence of gaseous transfer between the colon and blood stream on percentage gas compositions of intestinal flatus in man. Am J Physiol 1948; 153: 47582.
  • 110
    Levitt MD. Intestinal gas production – recent advances in flatology. N Engl J Med 1980; 302: 14745.
  • 111
    Suarez F, Furne J, Springfield J, Levitt M. Insights into human colonic physiology obtained from the study of flatus composition. Am J Physiol Gastrointest Liver Physiol 1997; 35: G102833.
  • 112
    Flourie B, Pellier P, Florent C, Marteau P, Pochart P, Rambaud JC. Site and substrates for methane production in human colon. Am J Physiol 1991; 260: G7527.
  • 113
    Bredenoord AJ, Weusten BLAM, Sifrim D, Timmer R, Smout AJPM. Aerophagia, gastric, and supragastric belching: a study using intraluminal electrical impedance monitoring. Gut 2004; 53: 15615.
  • 114
    Strocchi A, Levitt MD. Factors affecting hydrogen production and consumption by human fecal flora. The critical roles of hydrogen tension and methanogenesis. J Clin Invest 1992; 89: 130411.
  • 115
    Bassotti G, Germani U, Morelli A. Flatus-related colorectal and anal motor events. Dig Dis Sci 1996; 41: 3358.
  • 116
    Serra J, Azpiroz F, Malagelada JR. Intestinal gas dynamics and tolerance in humans. Gastroenterology 1998; 115: 54250.
  • 117
    Galati JS, Mckee DP, Quigley EMM. Response to intraluminal gas in irritable-bowel-syndrome – motility versus perception. Dig Dis Sci 1995; 40: 13817.
  • 118
    Harder H, Serra J, Azpiroz F, Passos MC, Aguade S, Malagelada JR. Intestinal gas distribution determines abdominal symptoms. Gut 2003; 52: 170813.
  • 119
    Serra J, Azpiroz F, Malagelada JR. Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation. Am J Physiol Gastrointest Liver Physiol 2001; 281: G13843.
  • 120
    Harder H, Serra J, Azpiroz F, Malagelada JR. Reflex control of intestinal gas dynamics and tolerance in humans. Am J Physiol Gastrointest Liver Physiol 2004; 286: G8994.
  • 121
    Serra J, Azpiroz F, Malagelada JR. Gastric distension and duodenal lipid infusion modulate intestinal gas transit and tolerance in humans. Am J Gastroenterol 2002; 97: 222530.
    Direct Link:
  • 122
    Harder H, Hernando-Harder AC, Franke A, Erguel GS, Krammer HJ, Singer MV. Duodenal infusion of different nutrients and the site of gaseous stimulation influence intestinal gas dynamics. Scand J Gastroenterol 2006; 41: 294301.
  • 123
    Serra J, Salvioli B, Azpiroz F, Malagelada JR. Lipid-induced intestinal gas retention in irritable bowel syndrome. Gastroenterology 2002; 123: 7006.
  • 124
    Pironi L, Stanghellini V, Miglioli M et al. Fat-induced ileal brake in humans – a dose-dependent phenomenon correlated to the plasma-levels of peptide-YY. Gastroenterology 1993; 105: 7339.
  • 125
    Hernando-Harder AC, Serra J, Azpiroz F, Malagelada JR. Sites of symptomatic gas retention during intestinal lipid perfusion in healthy subjects. Gut 2004; 53: 6615.
  • 126
    Dainese R, Serra J, Azpiroz F, Malagelada JR. Influence of body posture on intestinal transit of gas. Gut 2003; 52: 9714.
  • 127
    Dainese R, Serra J, Azpiroz F, Malagelada JR. Effects of physical activity on intestinal gas transit and evacuation in healthy subjects. Am J Med 2004; 116: 5369.
  • 128
    Caldarella MP, Serra J, Azpiroz F, Malagelada JR. Prokinetic effects in patients with intestinal gas retention. Gastroenterology 2002; 122: 174855.
  • 129
    Salvioli B, Serra J, Azpiroz F et al. Origin of gas retention and symptoms in patients with bloating. Gastroenterology 2005; 128: 5749.
  • 130
    Salvioli B, Serra J, Azpiroz F, Malagelada JR. Impaired small bowel gas propulsion in patients with bloating during intestinal lipid infusion. Am J Gastroenterol 2006; 101: 18537.
    Direct Link:
  • 131
    Passos MC, Serra J, Azpiroz F, Tremolaterra F, Malagelada JR. Impaired reflex control of intestinal gas transit in patients with abdominal bloating. Gut 2005; 54: 3448.
  • 132
    Levitt MD, Furne J, Olsson S. The relation of passage of gas on abdominal bloating to colonic gas production. Ann Intern Med 1996; 124: 4224.
  • 133
    King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 11879.
  • 134
    Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333: 14.
  • 135
    Nelis GF, Vermeeren MA, Jansen W. Role of fructose-sorbitol malabsorption in the irritable bowel syndrome. Gastroenterology 1990; 99: 101620.
  • 136
    Whitehead WE, Engel BT, Schuster MM. Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig Dis Sci 1980; 25: 40413.
  • 137
    Serra J, Azpiroz F, Malagelada JR. Modulation of gut perception in humans by spatial summation phenomena. J Physiol 1998; 506: 57987.
  • 138
    Serra J, Azpiroz F, Malagelada JR. Perception and reflex responses to intestinal distention in humans are modified by simultaneous or previous stimulation. Gastroenterology 1995; 109: 17429.
  • 139
    Poynard T, Hernandez M, Xu P et al. Visible abdominal distension and gas surface: description of an automatic method of evaluation and application to patients with irritable bowel syndrome and dyspepsia. Eur J Gastroenterol Hepatol 1992; 4: 8316.
  • 140
    Maxton DG, Martin DF, Whorwell P, Godfrey M. Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms. Gut 1991; 32: 6624.
  • 141
    Lea R, Houghton LA, Reilly B, Whorwell PJ. Is abdominal bloating related to physical distension in patients with irritable bowel syndrome (IBS)? Gastroenterology 2003; 124: A145.
  • 142
    Tremolaterra F, Villoria A, Azpiroz F, Serra J, Aguade S, Malagelada JR. Impaired viscerosomatic reflexes and abdominal-wall dystony associated with bloating. Gastroenterology 2006; 130: 10628.
  • 143
    Bearcroft CP, Perrett D, Farthing MJG. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998; 42: 426.
  • 144
    Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003; 52: 66370.
  • 145
    Ragnarsson G, Bodemar G. Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients’ description of diarrhoea, constipation and symptom variation during a prospective 6 week study. Eur J Gastroenterol Hepatol 1998; 10: 41521.
  • 146
    Coates MD, Mahoney CR, Linden DR et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 165764.
  • 147
    Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98: 157883.
    Direct Link:
  • 148
    Andrews C, Camilleri M, Bharucha AE et al. Serotonin-transporter promoter genotype and SERT mRNA expression in mucosal biopsies of patients with irritable bowel syndrome. Gastroenterology (abstract) 2006; 130: P43.
  • 149
    Pata C, Erdal ME, Derici E, Yazar A, Kanik A, Ulu O. Serotonin transporter gene polymorphism in irritable bowel syndrome. Am J Gastroenterol 2002; 97: 17804.
    Direct Link:
  • 150
    Yeo A, Boyd P, Lumsden S et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhea-predominant irritable bowel syndrome in women. Gut 2004; 53: 14528.
  • 151
    Kim HJ, Camilleri M, Carlson PJ et al. Association of distinct α2 adrenoceptor and serotonin-transporter polymorphisms associated with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004; 53: 82937.
  • 152
    Camilleri M. Commentary. Is there a SERT-ain association with IBS? Gut 2004; 53: 13969.
  • 153
    Camilleri M, Atanasova E, Carlson PJ et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant IBS. Gastroenterology 2002; 123: 42532.
  • 154
    Von Der Ohe M, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993; 329: 10738.
  • 155
    Von Der Ohe MR, Camilleri M, Kvols LK. A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology 1994; 106: 11849.
  • 156
    Saslow SB, Scolapio JS, Camilleri M et al. Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhea. Gut 1998; 42: 62834.
  • 157
    Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized control trials. Neurogastroenterol Motil 2003; 15: 7986.
  • 158
    Williams AJ, Merrick MV, Eastwood MA. Idiopathic bile acid malabsorption – a review of clinical presentation, diagnosis, and response to treatment. Gut 1991; 32: 10046.
  • 159
    Oddsson E, Rask-Madsen J, Krag E. A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scand J Gastroenterol 1978; 13: 40816.
  • 160
    Sciarretta G, Fagioli G, Furno A et al. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut 1987; 28: 9705.
  • 161
    Spiller RC, Brown ML, Phillips SF. Decreased fluid tolerance, accelerated transit, and abnormal motility of the human colon induced by oleic acid. Gastroenterology 1986; 91: 1007.
  • 162
    Kamath PS, Phillips SF, O'Connor MK, Brown ML, Zinsmeister AR. Colonic capacitance and transit in man: modulation by luminal contents and drugs. Gut 1990; 31: 4439.
  • 163
    Kamath PS, Phillips SF, Zinsmeister AR. Short-chain fatty acids stimulate ileal motility in humans. Gastroenterology 1988; 95: 14961502.
  • 164
    Kruis W, Haddad A, Phillips SF. Chenodeoxycholic and ursodeoxycholic acids alter motility and fluid transit in the canine ileum. Digestion 1986; 34: 18595.
  • 165
    Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ, Cook IJ. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol 2002; 282: G4439.
  • 166
    Fukumoto S, Tatewaki M, Yamada T et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol 2003; 284: R126976.
  • 167
    Cherbut C, Ferrier L, Roze C et al. Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat. Am J Physiol 1998; 275: G141522.
  • 168
    Pimentel M, Lin HC, Enayati P et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol 2006; 290: 6108995.
  • 169
    Malinen E, Rinttila T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 37382.
    Direct Link:
  • 170
    Husebye E, Hellstrom PM, Sundler F, Chen J, Midtvedt T. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol 2001; 280: G36880.
  • 171
    Marshall JK, Thabane M, Garg AX et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004; 20: 131722.
  • 172
    Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 12318.
    Direct Link:
  • 173
    Kim HJ, Camilleri M, McKinzie S et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895904.
  • 174
    Quigley E, O'Mahony L, McCarthy J et al. Probiotics for the irritable bowel syndrome (IBS): a randomized, double-blind, placebo-controlled comparison of Lactobacillus and Bifidobacterium species. Gastroenterology 2002; 122: A59.
  • 175
    Kim HJ, Vazquez Roque MI, Camilleri M et al. A randomized, controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 68796.
  • 176
    Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind, randomized, control trial. J Pediatr 2005; 147: 197201.
  • 177
    Lupascu A, Gabrielli M, Lauritano EC et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 115760.
  • 178
    Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 2005; 100: 156670.
    Direct Link:
  • 179
    Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 4129.
  • 180
    Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 32633.
    Direct Link:
  • 181
    Kalantar JS, Locke GR III, Zinsmeister AR, Beighley CM, Talley NJ. Familial aggregation of irritable bowel syndrome: a prospective study. Gut 2003; 52: 17037.
  • 182
    Locke GR III, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ III. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000; 75: 90712.
  • 183
    Morris-Yates A, Talley NJ, Boyce PM, Nandurkar S, Andrews G. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 1998; 93: 13117.
    Direct Link:
  • 184
    Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001; 121: 799804.
  • 185
    Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 913.
  • 186
    Andresen V, Camilleri M, Kim HJ et al. Is there an association between GNβ3 C825T genotype and lower functional gastrointestinal disorders? Gastroenterology 2006; 130: 198594.
  • 187
    Lesch KP, Bengel D, Heils A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 152731.